Canada Markets open in 4 hrs 53 mins

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0500+0.0150 (+42.86%)
At close: 03:45PM EST
Full screen
Previous Close0.0350
Bid0.0350 x 0
Ask0.0500 x 0
Day's Range0.0400 - 0.0500
52 Week Range0.0200 - 0.1100
Avg. Volume200,182
Market Cap6.632M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire

    Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

    VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America. Zimed® PF is the first prostagland

  • Simply Wall St.

    Aequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

    Aequus Pharmaceuticals ( CVE:AQS ) Third Quarter 2022 Results Key Financial Results Revenue: CA$347.9k (down 51% from...

  • GlobeNewswire

    Aequus Reports Third Quarter 2022 Financial Highlights

    VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Financial Report Highlights Aequus reported